This article was originally published in The Gray Sheet
Two firms sign a definitive agreement for EG&G to acquire Wallac, a unit of Procordia AB, for approximately $46 mil. Headquartered in Finland and with employees in Scandinavia, the U.K. and the U.S., Wallac posted roughly $50 mil. in 1992 sales. The producer of analytical and diagnostic systems, instruments and reagents will report to EG&G's instruments division, which markets medical, environmental and analytic monitoring products and accounts for approximately $227 mil. of EG&G's $2.7 bil. in annual revenues.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.